REGENXBIO Inc. (RGNX)
| Market Cap | 541.79M |
| Revenue (ttm) | 87.82M |
| Net Income (ttm) | -290.01M |
| Shares Out | 51.70M |
| EPS (ttm) | -5.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,356,421 |
| Open | 10.22 |
| Previous Close | 10.24 |
| Day's Range | 9.94 - 10.78 |
| 52-Week Range | 5.46 - 16.19 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 24.36 (+132.44%) |
| Earnings Date | Aug 6, 2026 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12... [Read more]
Financial Performance
In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for RGNX stock is "Buy." The 12-month stock price target is $24.36, which is an increase of 132.44% from the latest price.
News
Regenxbio completes dosing in confirmatory study of RGX-202
Regenxbio (RGNX) announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy. This milestone positions Re...
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interest On track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting poten...
Regenxbio price target raised to $32 from $27 at Baird
Baird raised the firm’s price target on Regenxbio (RGNX) to $32 from $27 and keeps an Outperform rating on the shares. The firm updated its model the reflect the FDA-aligned…
H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission
After Regenxbio (RGNX) announced that it has aligned with the FDA regarding the resubmission of the Biologics License Application for Navsunli for Mucopolysaccharidosis II or Hunter syndrome, H.C. Wai...
Regenxbio aligns with FDA on path forward for Navsunli
Regenxbio (RGNX) announced it has aligned with the U.S. FDA regarding the next steps needed for a potential accelerated approval of Navsunli, the only potential one-time treatment and gene therapy…
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE ® study will be reviewed on an expedited basis for approval via the accelerated approval pathway The Company ...
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio , the Wall Street Journal reported on Monday.
Regenxbio up 25% after saying FDA will reverse rejection, consider application
Regenxbio (RGNX) shares are up $1.97, or 25% to $9.77 in pre-market trading after after Chief Executive Curran Simpson said the Food and Drug Administration has agreed to reverse its…
Regenxbio tells WSJ that FDA will reverse rejection of drug
Regenxbio (RGNX) Chief Executive Curran Simpson said the Food and Drug Administration has agreed to reverse its rejection of an experimental gene therapy for a rare and fatal brain disease…
FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
The company plans to refile its application for its gene therapy for a fatal brain disease after the FDA dropped demands to give a placebo to some study subjects.
Regenxbio price target lowered to $26 from $30 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $26 from $30 and keeps a Buy rating on the shares. The firm says RGX202 deliveded…
REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026
Plans are underway for a rolling BLA filing for Duchenne gene therapy, with strong efficacy and safety data supporting accelerated approval. Wet AMD pivotal trials are well-powered and on track, while the Hunter program is advancing post-clinical hold. Patient advocacy and product differentiation remain central.
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare Confere...
Regenxbio price target lowered to $16 from $17 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Regenxbio (RGNX) to $16 from $17 and keeps an Overweight rating on the shares.
Regenxbio price target lowered to $14 from $25 at BofA
BofA lowered the firm’s price target on Regenxbio (RGNX) to $14 from $25 and keeps a Buy rating on the shares. The firm views the RGX-202 AFFINITY DUCHENNE topline update…
Regenxbio price target lowered to $12 from $37 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Regenxbio (RGNX) to $12 from $37 and keeps an Overweight rating on the shares. The firm thinks further updates on…
REGENXBIO Earnings release: Q1 2026
REGENXBIO released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
REGENXBIO Quarterly report: Q1 2026
REGENXBIO has published its Q1 2026 quarterly earnings report on May 14, 2026.
Regenxbio reports Q1 EPS ($1.72) vs. 12c last year
Reports Q1 revenue $6.4M vs. $89M last year. “REGENXBIO (RGNX) enters a transformative year with positive momentum, reaching significant late-stage milestones to support our potential first- and best-...
Regenxbio expects cash, equivalents to fund operations into early 2027
Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $150.5M as of March 31 to fund its operations into early 2027. This cash runway guidance is…
Regenxbio’s RGX-202 shows efficacy in Phase 3 Duchenne trial
Regenxbio (RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene ther...
REGENXBIO Transcript: Study result
Pivotal phase III data for RGX-202 in Duchenne Muscular Dystrophy showed high microdystrophin expression, strong correlation with functional improvement, and a favorable safety profile. Investigators and families observed meaningful benefits, supporting plans for accelerated approval in 2027.
REGENXBIO Press release: Study result
REGENXBIO issued a press release on May 14, 2026, disclosing material business information to investors.
REGENXBIO Slides: Study result
REGENXBIO has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE ® study of RGX-202 Primary endpoint achieved with high statistical significance Statistically significant correlatio...